Myobloc® for the treatment of benign essential blepharospasm in patients refractory to Botox®

Ophthalmic Plastic and Reconstructive Surgery

Volumn 22, Issue 3, 2006, Pages 173-177

  Dutton, Jonathan J ^a,b   White, Jeffrey J ^a   Richard, Michael J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; BLURRED VISION; CAPILLARY RESISTANCE; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DIPLOPIA; DOSE RESPONSE; DRY EYE; ECCHYMOSIS; ECTROPION; ENTROPION; EPIPHORA; EYELID EDEMA; FACE MUSCLE; FEMALE; HEADACHE; HEMIFACIAL SPASM; HUMAN; INJECTION SITE PAIN; KERATITIS; MALE; MOUTH MALFORMATION; MUSCLE WEAKNESS; PARESTHESIA; PRIORITY JOURNAL; PTOSIS; SIDE EFFECT; TREATMENT DURATION; XEROSTOMIA; DRUG RESISTANCE; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745313013     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iop.0000217382.33972.c4     Document Type: Article

References (29)

1. Dutton JJ, Buckley EG. Botulinum toxin in the management of blepharospasm. Arch Neurol 1986;43:380-2.
2. Brin MF, Fahn S, Moskowitz C, et al. Localized injection of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-54.
3. Tsui JK, Eisen A, Stoessel AJ, et al. Double blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-7.
4. Marin G, Cadeddu F, Brisinda D, et al. Management of bladder, prostatic, and pelvic floor disorders with botulinum neurotoxin. Curr Med Chem 2005;12:247-65.
5. Kaltreider SA, Kennedy RH, Woog JJ, et al. Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology. Ophthalmology 2005;112:1159-67.
6. Dutton JJ. Botulinum-A toxin in treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51-65.
7. Birklein F, Walther D, Bigalke H, et al. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. Ann Neurol 2002;52:68-73.
8. Dressler D, Dirnberger G. Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 2001;45:257-60.
9. Kessler KR, Benecke R. The EBD test: a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 1997;12:95-9.
10. Biglan AW, Kim SJ. Management of hemifacial spasm with botulinum A toxin. In: Jankovic J, Hallett M (eds), Therapy With Botulinum Toxin. New York: Marcel Dekker, 1994:353-9.
11. Borodic GE, Pearce B. New concepts in botulinum toxin therapy. Drug Safety 1994;11:145-52.
12. Hathaway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds), Therapy With Botulinum Toxin. New York: Marcel Dekker, 1994:103-4.
13. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;199(suppl 8):S92-100.
14. Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum A toxin. Ophthalmology 1993;101:1158-9.
15. Dressler D, Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 2004;52:132-5.
16. Berman B, Seeberger L, Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 2004;20:233-7.
17. Lew M, Adornato B, Duane D, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
18. Truong DD, Cullis PA, O'Brien CF, et al. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov Disord 1997;12:772-5.
19. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-83.
20. Costa J, Borges A, Espirito-Santo C, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005;25:CD004314.
21. Colosimo C, Chianese M, Giovanelli M, et al. Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol Neurosurg Psychiatry 2003;74:687.
22. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003;250:967-9.
23. Guntinas-Lichius O. Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A. Laryngoscope 2003;113:743-5.
24. Dutton JJ, Buckley EG. Long-term results and complications of botulinum toxin in the treatment of blepharospasm. Ophthalmology 1988;95:1529-34.
25. Caruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987;14:42-5.
26. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum toxin A injections. Mov Disord 1994;9:31-9.
27. Borodic GE, Pearce LB, Smith KL, et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 1993;9:182-90.
28. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51-65.
29. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin as a treatment for blepharospasm. Arch Ophthalmol 1985;103:347-50.